Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 33,144 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Cystic Fibrosis, Anemia, Iron-Deficiency
Interventions: Ferrous sulfate 325mg, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Portland, Maine • Lebanon, New Hampshire

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: Liprotamase, Placebo; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 26 more

Conditions: Influenza
Interventions: VAL-339851, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Generalized Anxiety Disorder, Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol; Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more

Conditions: Osteoporosis
Interventions: ibandronate, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 14
States / cities: Upland, California • Boulder, Colorado • Lakewood, Colorado + 10 more

Conditions: Stress, Acute Stress Reaction, Breathing Techniques, Cognitive Performance
Interventions: Box Breathing, Prolonged Exhalation, Normal Breathing; Other
Lead sponsor: Texas State University; Other
Eligibility: 18 Years to 39 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Marcos, Texas

Conditions: Lumbar Spinal Stenosis, Thoracic Spinal Stenosis
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Venous Thromboembolism
Interventions: Semuloparin sodium, Enoxaparin sodium, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Schizophrenia
Interventions: Brain Fitness Program (BFP), Cognitive Package (Cogpack), Commercial Computer Games (Sporcle); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 25 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Los Angeles, California • West Los Angeles, California

Conditions: Systemic Lupus Erythematosus
Interventions: Ianalumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 22
States / cities: Anniston, Alabama • Burbank, California • La Jolla, California + 19 more

Conditions: PFIC1, PFIC2
Interventions: A4250 (odevixibat), Placebo; Drug
Lead sponsor: Albireo; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more

Conditions: Breast Cancer
Interventions: metformin hydrochloride, placebo; Drug · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years to 74 Years
Enrollment: 3,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 280
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Scottsdale, Arizona + 213 more

Conditions: Node Positive HER2 Negative Breast Cancer
Interventions: Placebo, Aspirin; Other · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 69 Years
Enrollment: 3,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1426
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more

Conditions: Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions: standard therapy, activated recombinant human factor VII, placebo; Procedure · Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Prostate Cancer, Lower Urinary Tract Symptoms, Radioactive Seed Implantation
Interventions: Botox injection, Saline injection; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pain
Interventions: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%), Placebo Peel; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Substance Abuse, Substance Dependence
Interventions: Behavioral Intervention; Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 16 Years to 44 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Glen Oaks, New York • Manhasset, New York

Conditions: Major Depression
Interventions: Psilocybin, modafinil, zolpidem, pimavanserin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Minneapolis, Minnesota + 1 more

Conditions: Lupus Nephritis
Interventions: Voclosporin, Placebo Oral Capsule; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 59
States / cities: Huntsville, Alabama • Phoenix, Arizona • Beverly Hills, California + 47 more

Conditions: COVID-19
Interventions: Rivaroxaban, Placebo; Drug
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Rogers, Arkansas • Los Angeles, California • San Diego, California + 14 more

Conditions: Psychosis, Sleep
Interventions: oral melatonin tablets (NatureMade brand), Placebo; Drug · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 11 Years to 30 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dry Eye
Interventions: Omega 3 fatty acid, Placebos; Drug
Lead sponsor: OmegaD LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Newport Beach, California • Westminster, California • Largo, Florida + 11 more

Conditions: Pain
Interventions: Lidocaine-Prilocaine Cream, Placebo Cream, 1% Lidocaine Paracervical Block; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo

The Effect of Breathing on Cognitive Performance and Stress

Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Botulinum Toxin Injection With Prostate Brachytherapy

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children

Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole

Psilocybin for Depression in Veterans

Aurinia Renal Response in Active Lupus With Voclosporin

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms

Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

Lidocaine-Prilocaine Cream in Conjunction With Paracervical Block for Pain With Abortion